Please login to the form below

Not currently logged in

Galapagos and Janssen end inflammation alliance

Galapagos regains right to GLPG1690

GalapagosJanssen and Galapagos have mutually agreed to terminate their inflammation alliance and option agreements. 

Alongside other candidates, Galapagos will obtain all rights to drug GLPG1690, a selective autotaxin inhibitor preparing for phase II clinical trial in idiopathic pulmonary fibrosis (IPF), a chronic and ultimately fatal disease characterised by a progressive decline in lung function. 

Dr Piet Wigerinck, chief scientific officer at Galapagos, commented: “We are pleased to regain the rights to GLPG1690 to pursue the most suitable clinical application of autotaxin inhibition. 

“The alliance with Janssen has been underway since October 2007 and has generated three clinical molecules, two of which are now proprietary phase II assets of Galapagos: GLPG1205 and GLPG1690. This programme is a valuable component of our development portfolio and regaining the rights is a next step in our transformation into a mature biotech company with a proprietary product pipeline.”

Galapagos identified autotaxin as having a key role to play in inflammation with additional studies suggesting it may also be significant against metabolic disease, arthritic pain, oncology and lung disease. 

Article by
Kirstie Pickering

18th March 2015

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company

WCG is an independent, global agency specialising in healthcare communications. Our value as a company is about being the positive...

Latest intelligence

Waking the sleeping giant
The lights are coming on for healthcare delivery in Africa...
How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...